Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Akerley

Showing results (181-190 of 227) with videos related to

Pageof 23
Sort By:
Oncotarget|February 3, 2022
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. studyConnor Willis, Hillevi Bauer, Trang H Au, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group StudiesThomas E Stinchcombe, Ying Zhang, Everett E Vokes, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung CancerArjun Pennathur, David Midthun, Malgorzata Wojtowicz, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
Nature Medicine|September 30, 2024
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumabTyler J Alban, Nadeem Riaz, Prerana Parthasarathy, et al.
BMC Cancer|May 7, 2021
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarkerKristen C Kelley, Kenneth F Grossman, Mary Brittain-Blankenship, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Journal for Immunotherapy of Cancer|October 28, 2021
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancerPatricia Rich, R Brian Mitchell, Eric Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Pageof 23

Showing results (181-190 of 227) with videos related to

Sort By:
Pageof 23
Oncotarget|February 3, 2022
Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. studyConnor Willis, Hillevi Bauer, Trang H Au, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2017
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group StudiesThomas E Stinchcombe, Ying Zhang, Everett E Vokes, et al.
Medrxiv : the Preprint Server for Health Sciences|July 16, 2025
A Multicenter Pilot Study of MUC1 Vaccine in Current and Former Smokers at High Risk for Lung CancerArjun Pennathur, David Midthun, Malgorzata Wojtowicz, et al.
JTO Clinical and Research Reports|September 30, 2021
Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With <i>EGFR</i>-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized StudyJames Chih-Hsin Yang, Karen L Reckamp, Young-Chul Kim, et al.
The Lancet. Oncology|September 1, 2023
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 studyTiciana Leal, Rupesh Kotecha, Rodryg Ramlau, et al.
Nature Medicine|September 30, 2024
Neoantigen immunogenicity landscapes and evolution of tumor ecosystems during immunotherapy with nivolumabTyler J Alban, Nadeem Riaz, Prerana Parthasarathy, et al.
BMC Cancer|May 7, 2021
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarkerKristen C Kelley, Kenneth F Grossman, Mary Brittain-Blankenship, et al.
Plos One|November 28, 2018
Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLCMichael E Goldberg, Meagan Montesion, Lauren Young, et al.
Journal for Immunotherapy of Cancer|October 28, 2021
Real-world performance of blood-based proteomic profiling in first-line immunotherapy treatment in advanced stage non-small cell lung cancerPatricia Rich, R Brian Mitchell, Eric Schaefer, et al.
Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.
Pageof 23